Join Growin Stock Community!

Igc pharma, inc.IGC.US Overview

US StockHealthcare
(No presentation for IGC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IGC AI Insights

IGC Overall Performance

IGC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IGC Recent Performance

-0.94%

Igc pharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IGC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IGC Key Information

IGC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IGC Profile

India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand. The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts. It operates in the United States, India, Colombia, and Hong Kong. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Price of IGC

IGC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IGC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23.83
PB Ratio
3.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
46.20%
Net Margin
-582.82%
Revenue Growth (YoY)
-6.51%
Profit Growth (YoY)
-23.16%
3-Year Revenue Growth
-1.85%
3-Year Profit Growth
-9.82%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23.83
PB Ratio
3.34
Price-to-FCF
-
Gross Margin
46.20%
Net Margin
-582.82%
Revenue Growth (YoY)
-6.51%
Profit Growth (YoY)
-23.16%
3-Year Revenue Growth
-1.85%
3-Year Profit Growth
-9.82%

  • When is IGC's latest earnings report released?

    The most recent financial report for Igc pharma, inc. (IGC) covers the period of 2026Q2 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IGC's short-term business performance and financial health. For the latest updates on IGC's earnings releases, visit this page regularly.

  • What is the operating profit of IGC?

    According to the latest financial report, Igc pharma, inc. (IGC) reported an Operating Profit of -2.9M with an Operating Margin of -1,517.8% this period, representing a decline of 64.72% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IGC's revenue growth?

    In the latest financial report, Igc pharma, inc. (IGC) announced revenue of 191K, with a Year-Over-Year growth rate of -53.64%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does IGC have?

    At the end of the period, Igc pharma, inc. (IGC) held Total Cash and Cash Equivalents of 1.28M, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IGC go with three margins increasing?

    In the latest report, Igc pharma, inc. (IGC) did not achieve the “three margins increasing” benchmark, with a gross margin of 51.8%%, operating margin of -1,517.8%%, and net margin of -953.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IGC's profit trajectory and future growth potential.

  • What is the FCF of IGC?

    Igc pharma, inc. (IGC)'s Free Cash Flow (FCF) for the period is -2.14M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 112.29% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.